News

The Manila Times on MSN13h
Kiniksa Pharmaceuticals, Ltd.: Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $590 - $605 million -- KPL-387 ...
Taiwan News12h
Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting
TNX-1700 is in preclinical development for gastric and colorectal cancers ...